Sunscreen Data Guidance Risk/Benefit Balance Uneven – Comments
This article was originally published in The Tan Sheet
Executive Summary
FDA's suggestion of maximal use trials to assess the systemic absorption potential for proposed sunscreen ingredients will delay consumer access to new broad-spectrum sunscreens without a sound scientific basis, say PASS, the American Cancer Society and American Academy of Dermatology Association.